CoChat
Cited by 210

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

Open access
Mlecnik, Bernhard, Bifulco, Carlo, Bindea, Gabriela, Marliot, Florence, Lugli, Alessandro, Lee, J. Jack, Zlobec, Inti, Rau, Tilman T., Berger, Martin D., Nagtegaal, Iris D., Vink-Börger, Elisa, Hartmann, Arndt, Geppert, Carol, Kolwelter, Julie, Merkel, Susanne, Grützmann, Robert, Van den Eynde, Marc, Jouret-Mourin, Anne, Kartheuser, Alex, Léonard, Daniel, Remue, Christophe, Wang, Julia Y., Bavi, Prashant, Roehrl, Michael H. A., Ohashi, Pamela S., Nguyen, Linh T., Han, SeongJun, MacGregor, Heather L., Hafezi-Bakhtiari, Sara, Wouters, Bradly G., Masucci, Giuseppe V., Andersson, Emilia K., Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Nemejcova, Kristyna, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Ciliberto, Gennaro, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Fredriksen, Tessa, Buttard, Bénédicte, Lafontaine, Lucie, Bruni, Daniela, Lanzi, Anastasia, El Sissy, Carine, Haicheur, Nacilla, Kirilovsky, Amos, Berger, Anne, Lagorce, Christine, Paustian, Christopher, Ballesteros-Merino, Carmen, Dijkstra, Jeroen, van de Water, Carlijn, van Lent–van Vliet, Shannon, Knijn, Nikki, Muşină, Ana-Maria, Scripcariu, Dragos-Viorel, Popivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Torigoe, Toshihiko, Sato, Noriyuki, Furuhata, Tomohisa, Takemasa, Ichiro, Itoh, Kyogo, Patel, Prabhu S., Vora, Hemangini H., Shah, Birva, Patel, Jayendrakumar B., Rajvik, Kruti N., Pandya, Shashank J., Shukla, Shilin N., Wang, Yili, Zhang, Guanjun, Kawakami, Yutaka, Marincola, Francesco M., Ascierto, Paolo A., Fox, Bernard A., Pagès, Franck, Galon, Jérôme · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR). METHODS: An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia). CD3+ and cytotoxic CD8+ T lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The primary end point was TTR. Secondary end points were overall survival (OS), disease-free survival (DFS), prognosis in microsatellite stable (MSS) status, and predictive value of efficacy of chemotherapy. RESULTS: Patients with a high Immunoscore presented with the lowest risk of recurrence, in both cohorts. Recurrence-free rates at 3 years were 56.9% (95% CI, 50.3% to 64.4%), 65.9% (95% CI, 60.8% to 71.4%), and 76.4% (95% CI, 69.3% to 84.3%) in patients with low, intermediate, and high immunoscores, respectively (hazard ratio [HR; high v low], 0.48; 95% CI, 0.32 to 0.71; P = .0003). Patients with high Immunoscore showed significant association with prolonged TTR, OS, and DFS (all P < .001). In Cox multivariable analysis stratified by participating center, Immunoscore association with TTR was independent (HR [high v low], 0.41; 95% CI, 0.25 to 0.67; P = .0003) of patient’s sex, T stage, N stage, sidedness, and microsatellite instability status. Significant association of a high Immunoscore with prolonged TTR was also found among MSS patients (HR [high v low], 0.36; 95% CI, 0.21 to 0.62; P = .0003). Immunoscore had the strongest contribution χ2 proportion for influencing survival (TTR and OS). Chemotherapy was significantly associated with survival in the high-Immunoscore group for both low-risk (HR [chemotherapy v no chemotherapy], 0.42; 95% CI, 0.25 to 0.71; P = .0011) and high-risk (HR [chemotherapy v no chemotherapy], 0.5; 95% CI, 0.33 to 0.77; P = .0015) patients, in contrast to the low-Immunoscore group ( P > .12). CONCLUSION: This study shows that a high Immunoscore significantly associated with prolonged survival in stage III CC. Our findings suggest that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.03205

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 210

Metadata

Authors
Mlecnik, B., Bifulco, C., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., Vink-Börger, E., Hartmann, A., Geppert, C., Kolwelter, J., Merkel, S., Grützmann, R., Van den Eynde, M., Jouret-Mourin, A., Kartheuser, A., Léonard, D., Remue, C., Wang, J. Y., Bavi, P., Roehrl, M. H. A., Ohashi, P. S., Nguyen, L. T., Han, S., MacGregor, H. L., Hafezi-Bakhtiari, S., Wouters, B. G., Masucci, G. V., Andersson, E. K., Zavadova, E., Vocka, M., Spacek, J., Petruzelka, L., Konopasek, B., Dundr, P., Skalova, H., Nemejcova, K., Botti, G., Tatangelo, F., Delrio, P., Ciliberto, G., Maio, M., Laghi, L., Grizzi, F., Fredriksen, T., Buttard, B., Lafontaine, L., Bruni, D., Lanzi, A., El Sissy, C., Haicheur, N., Kirilovsky, A., Berger, A., Lagorce, C., Paustian, C., Ballesteros-Merino, C., Dijkstra, J., van de Water, C., van Lent–van Vliet, S., Knijn, N., Muşină, A.-M., Scripcariu, D.-V., Popivanova, B., Xu, M., Fujita, T., Hazama, S., Suzuki, N., Nagano, H., Okuno, K., Torigoe, T., Sato, N., Furuhata, T., Takemasa, I., Itoh, K., Patel, P. S., Vora, H. H., Shah, B., Patel, J. B., Rajvik, K. N., Pandya, S. J., Shukla, S. N., Wang, Y., Zhang, G., Kawakami, Y., Marincola, F. M., Ascierto, P. A., Fox, B. A., Pagès, F., & Galon, J.
Venue
Journal of Clinical Oncology
Published
2020-11-01
Volume
38
Issue
31
Pages
3638-3651
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3083966623
Cited by
210
References
10
FWCI
10.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. https://app.cochat.ai/papers/10.1200/jco.19.03205
The paper
Mlecnik, B., Bifulco, C., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., Vink-Börger, E., Hartmann, A., Geppert, C., Kolwelter, J., Merkel, S., Grützmann, R., Van den Eynde, M., Jouret-Mourin, A., Kartheuser, A., . . . Galon, J. (2020). Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.03205

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.